Mineralys Therapeutics Q3 2026 Results: Net Loss of $57.3M, Loss Widens
Mineralys Therapeutics reported a net loss of $337.7 million for the nine months ended September 30, 2026, driven by a $200 million upfront license amendment payment and increased R&D and G&A expenses. The company ended the period with $624.7 million in cash, cash equivalents, and investments, and is awaiting an FDA decision on its NDA for lorundrostat with a PDUFA date of December 22, 2026.
- Key figure
- Net loss $57.3M